Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00737672 · ClinicalTrials.gov registry record · Phase 3
GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
A Phase 3 study, sponsored by W.L.Gore & Associates.
- Completed
- Registry status
- Phase 3
- Development phase
- 293
- Enrollment target
NCT00737672: Completed Phase 3 study, sponsored by W.L.Gore & Associates.
NCT00737672 is a Phase 3 study that has completed, run by W.L.Gore & Associates. The registered enrollment target is 293 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00737672, a Phase 3 study, has completed, sponsored by W.L.Gore & Associates.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 293 participants
- Enrollment target
Study Summary
The objective of the study is to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface when used to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis.
Primary Outcome
Kaplan-Meier estimate of the time interval of uninterrupted patency from initial study treatment to the next access thrombosis or intervention performed on the target lesion. Six-month estimate of target lesion primary patency derived from Kaplan-Meier curve.
Interventions
- PROCEDURE Percutaneous Transluminal Angioplasty
- DEVICE GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 293 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
What the finished NCT00737672 record still lists
NCT00737672 is an interventional study that assigns participants to a tested intervention. The registered 293 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which Percutaneous Transluminal Angioplasty is the first listed.
NCT00737672 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00737672 about?
NCT00737672 is a clinical study titled "GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis". The objective of the study is to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface when used to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis.
What is the current status of trial NCT00737672?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 293 participants. The study started on 2008-09. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00737672?
The interventions under investigation include: Percutaneous Transluminal Angioplasty (PROCEDURE), GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface (DEVICE).
Who is sponsoring clinical trial NCT00737672?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00737672's enrollment target sits among peer trials
293 1166th of 2000 higher than 835 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05775159 · 294 participants · Phase 2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- NCT06262113 · 294 participants · NA
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
- NCT06338865 · 294 participants · NA
Short Title: Standard vs. Lower Pressure Pneumoperitoneum
- NCT06395467 · 294 participants · NA
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia